Segments - Non-Opioid Pain Patches Market by Types (Lidocaine Patches, Diclofenac Patches, Methyl Salicylate Patches, Capsaicin Patches, Ketoprofen Patches, and Others), Distribution Channels (Hospitals, Online Pharmacies, and Drug Stores), and Regions (Asia Pacific, North America, Latin America, Europe and Middle East & Africa)- Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2023 – 2031
The global non-opioid pain patches market size was valued at USD 863.35 million in 2022 and is anticipated to reach USD 1.28 Billion by 2031 expand at a CAGR of 4.5% during the forecast period, 2023-2031. The growth of the market is attributed to the increasing number of acute and chronic pain related disorders, along with the health benefits that the non-opioid pain patches provided to each patient.
Non-Opioid pain patches have been introduced in early 2018 when the World Health Organization or the WHO census report stated that a large amount of the population were committing to death for the relief of pain, or the management of pain has been handled very poorly across the globe.
The Centre for Disease Control and Prevention along with the National Institute of Drug Abuse reported a disturbing census that over 90 Americans died of opioid overdose every day. The opioids were not legal and were largely made on non-directed or regulated laboratories and sold at high prices. The WHO announced the legality of non-opioid pain patches to be legal across the globe to remedy this situation.
Non-Opioid pain patches has mainly found applications which require the relief of severe, acute and chronic pain in most of the internal systems of the patient. It is a class of medication which can send reliefs, as well as cure addictions to unhealthy habits such as smoking. The prescriptions given by the physicians for the use of non-opioid pain patches becomes critical for the dosage and minimal requirements need to be met for using these patches. Using non-opioid patches on healthy individuals could be counter-productive in the long run.
The COVID-19 pandemic has reduced the growth of the global non-opioid pain patches market. Researchers and scientists were not able to recognize the co-relation between the coronavirus and non-opioid pain patches. However, once the COVID-19 pandemic ends and when vaccinations reach the majority population of the globe, the non-opioid pain patches market is set to boost its growth to a double digit CAGR.
The report on the global non-opioid pain patches market size includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Attributes |
Details |
Report Title |
Non-Opioid Pain Patches Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
Base Year |
2022 |
Historic Data |
2016–2021 |
Forecast Period |
2023–2031 |
Segmentation |
Types (Lidocaine Patches, Diclofenac Patches, Methyl Salicylate Patches, Capsaicin Patches, Ketoprofen Patches, and Others), and Distribution Channels (Hospitals, Online Pharmacies, and Drug Stores) |
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, Trends, and Revenue Forecast |
Key Players Covered in the Report |
Richmar Inc; Acorda Therapeutics; Teva Pharmaceutical Industries Ltd; GlaxoSmithKline plc; Endo Pharmaceuticals Inc; Hisamitsu Pharmaceutical Co Inc; IBSA Institut Biochimque SA; Alkermes; Teikoku Seiyaku Co Ltd; Capsugel; and Mylan NV |
Based on types, the global non-opioid pain patches market is segmented into lidocaine patches, diclofenac patches, methyl salicylate patches, capsaicin patches, ketoprofen patches, and others. The lidocaine patches segment is expected to constitute the major share of the market in 2019. These were the best patches available for the alleviant of pain, providing efficient drug delivery during the entire duration, and was available at low costs.
Meanwhile the diclofenac patches segment is anticipated to grow with a significant CAGR during the forecast period, 2021-2028. The safety profile of this class in patches was the highest and it also showed great signs of increasing efficacy rates. Researchers and scientists have focused more on diclofenac patches and believe they can even be effective to the patient’s neurological system.
On the basis of distribution channels, the global non-opioid pain patches market is divided into hospitals, online pharmacies, and drug stores. The hospitals segment is expected to constitute the major share of the market in 2019. The major reason attributing to this market growth is the frequent number of patient visits and admissions for the treatment of pain, particularly the patients suffering from multiple musculoskeletal diseases and other disorders which can cause chronic and acute pain.
There has been a long-term use of multiple painkillers which can usually bring an additional risk for medication-related adverse effects. This prompted physicians to prescribe oral drugs along with examinations from the hospitals, thereby increasing this segment market growth. Meanwhile the online pharmacies segment is anticipated to grow with a significant CAGR during the forecast period, 2023-2031.
The availability for the products present at online pharmacies can facilitate individuals for purchasing non-opioid patches for the alleviation chronic and acute pain. Now these patches can be procured without the need of a prescription, making users more convenient for purchasing from online pharmacies leading to the segment market growth.
On the basis of regions, the global non-opioid pain patches market is categorized as Asia Pacific, North America, Latin America, Europe and Middle East & Africa. The market in North America is expected to constitute a large share in 2019. This regional market growth can be attributed to the growing research & development expenditure along with the rising in adoption of the latest technology.
The demand of non-opioid pain patches is increasing in this region due to the presence of the major market players in the market, an advantage other regions do not have. The cost of expenditure is significantly lower in North America than that of other economies. According to the American Chiropractic Association, the total expenditure spent by Americans for the treatment of back aches is USD 50 billion.
Back pain along with upper respiratory infections are the most common disorders for which the patients visit their doctors. This results in therapies to combat the pain at minimum cost as the demand is huge. The non-opioid pain patches alleviates this pain, reduces the risk for various adverse effects, and will have a minute chance for being misused and ultimately leading to addiction, thereby increasing their demand to the highest compared to other regions.
However, the market in Asia Pacific is anticipated to expand at a significant CAGR during the forecast period, 2021-2028. There has been a sharp increase in the lifestyle-related disorders and with sedentary lifestyle, an increase in the patients suffering from acute and chronic pain became unavoidable.
Major developers of the non-opioid patches, mainly multinational pharmaceutical companies along with the help of clinical research organizations or the CROs, have started making efforts to improve the healthcare supply chain to guarantee the availability of these patches in this region. Latin America is another region which has observed immense burden to patients suffering from back pain along with other musculoskeletal and cardiovascular disorders.
This has slowly been added to the healthcare expenditures of this region. There has been an incremental increase in the patient count along with product adoption & cognizance which accelerated this regional market growth.
Major players competing in the global non-opioid pain patches market are Richmar Inc; Acorda Therapeutics; Teva Pharmaceutical Industries Ltd; GlaxoSmithKline plc; Endo Pharmaceuticals Inc; Hisamitsu Pharmaceutical Co Inc; IBSA Institut Biochimque SA; Alkermes; Teikoku Seiyaku Co Ltd; Capsugel; and Mylan NV.
These market players are involved in several business strategies such as mergers, acquisitions partnerships, collaborations, capacity expansion, and product launches to enhance their market shares. This market is widely fragmented to the point that numerous companies have been engaged to their own research and development studies to help the large global public from chronic pain.
The market players have started using a large range of technologies for the development of products for the facilitation of prolonged drug releases for increasing product penetration and consumer base. This market is also very competitive with respect to being a comparatively new market opening an intense competition between new entrants and exiting players.
Key market players have started engaging in numerous mergers and acquisition activities for the expansion of their product profiles. Acorda Therapeutics confirmed the acquisition of NeurogesX in 2018, after testing their two developed products five years ago and this strengthened their neuropathic pain management portfolios.
The acquired products were Phase Three-Stage Product NP-1998 and Qutenza which found applications in the treatment of diabetic neurotherapy and postherpetic neuralgia, respectively. The major market players also engaged in various collaborations with different distribution companies in order to increase in product penetration.
Richmar Inc declared the complete distribution of the product LidoFlex Pain Relief patch across the globe in 2019 with the help of Scrip Companies group, suppliers of physical therapy equipment, chiropractic products & supplies.